Pfizer's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Quote












Anonymous said:
Looks likes analysts don't buy the EP and EM story....I and F also seem to be signaling a u turn on Animal Health and Nutrition - double digit growth beats EP EM
Click to expand...

The businesses outside of Pharma have been the steady performers for years, generating growth, hundreds of millions in cash, and shielded us from patent expirations. Yet, like an ungrateful spouse, we take them for granted, ignore them for years, and then dump them for something sexier (biotechs, Pharmacia's Bextra, King's pain portfolio, ...), only to realize that they're all worse than what we shed like a dirty blanket.

I would leap at the opportunity to invest in the spinoffs. But don't trust me, ask J&J how that Consumer Products division has done for them since we sold it to them on the cheap...
 








Anonymous said:
You need to understand margins and profits a bit better. These are commodity markets, the margins suck.
Click to expand...

You, sir, are an idiot. You either:

1. Have NO CLUE what you are talking about;

2. Are talking out of your a$$

PAH has 70% gross margins, which I wouldn't consider "sucky" margins. Better yet, we have had generic competition for decades, yet continue to make millions. On the consumer side, it is much the same story: consistent margins, solid cash flow, no patent cliffs.

But hey, keep sitting on the Titanic and judging the smaller boats that float around you as you sink.
 




Anonymous said:
You, sir, are an idiot. You either:

1. Have NO CLUE what you are talking about;

2. Are talking out of your a$$

PAH has 70% gross margins, which I wouldn't consider "sucky" margins. Better yet, we have had generic competition for decades, yet continue to make millions. On the consumer side, it is much the same story: consistent margins, solid cash flow, no patent cliffs.

But hey, keep sitting on the Titanic and judging the smaller boats that float around you as you sink.
Click to expand...

The PP was correct, it's all about the margins. Pfizer will try to appear healthy with per unit margin increases. Not saying it's right, just that it happens.

Look at Lipitor, before it went generic Pfizer was making about $720 in profit per year per patient! Not bad.

Consumer products don't have the sizzle, takes hundreds of unit sales to make those types of profits. PAH is strong, I agree, but where's the sizzle? I haven't seen many breaking news articles about anaimal health, but seen alot about Apixiban.

Consumer health, PAH, and worst of all, you and I are considered commodities, live with it.
 




Anonymous said:
You, sir, are an idiot. You either:

1. Have NO CLUE what you are talking about;

2. Are talking out of your a$$

PAH has 70% gross margins, which I wouldn't consider "sucky" margins. Better yet, we have had generic competition for decades, yet continue to make millions. On the consumer side, it is much the same story: consistent margins, solid cash flow, no patent cliffs.

But hey, keep sitting on the Titanic and judging the smaller boats that float around you as you sink.
Click to expand...

Do you know what cost of sale is? You are a shrill, emotional wreck who spouts loud comments without an understanding of what your financial officers are looking at. Now take a valium and chill.
 




Anonymous said:
Do you know what cost of sale is? You are a shrill, emotional wreck who spouts loud comments without an understanding of what your financial officers are looking at. Now take a valium and chill.
Click to expand...

PAH is a $4 billion business with double-digit growth, FCF in the tens of millions and 70% margins. If you have any intelligence, it would be obvious to you that a company like this would get a P/E almost double PFE's. Therefore, selling it would be DILUTIVE to our market value. Compound that with the fact that we NEVER sell at a premium (we only OVERPAY), and the only conclusion is that the shareholders of this company, onlcluding you and me, will lose when we sell off the PAH and Nutrition divisions.

If you disagree with me, you don't need valium - you need Geodon.
 




EP questions were interesting. Wonder how EP compares to the cost of a true generics company. Many of the generic sourcing strategies are being reworked at a cost...so the cost within BU and on Enabling services must be high. Growth of EP share in EM also appears to be a concern for some of the analysts.
 




Anonymous said:
PAH is a $4 billion business with double-digit growth, FCF in the tens of millions and 70% margins. If you have any intelligence, it would be obvious to you that a company like this would get a P/E almost double PFE's. Therefore, selling it would be DILUTIVE to our market value. Compound that with the fact that we NEVER sell at a premium (we only OVERPAY), and the only conclusion is that the shareholders of this company, onlcluding you and me, will lose when we sell off the PAH and Nutrition divisions.

If you disagree with me, you don't need valium - you need Geodon.
Click to expand...

Well, I am sure glad the CEO addressed the world wide BRIBERY CHARGES that he happily provided along with all the other corrupt business practices currently enforced especially noted the latest "Pfired from Wyeth" sponsored poster symposiums that recently went over so well...geodon notwithstanding.
 




Top Bottom
Back
Quote